Pulmonx price target lowered to $5 from $6 at Canaccord

Canaccord analyst William Plovanic lowered the firm’s price target on Pulmonx (LUNG) to $5 from $6 and keeps a Buy rating on the shares. The firm said Q4 results came in largely inline as Management detailed the internal issues that weighed on performance last year and the actions taken to address them. as the company plans to focus on the fundamentals that brought success in the past.